We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies—Reply

Francesc Graus, MD, PhD1,2; Helena Ariño, MD1; Josep Dalmau, MD, PhD1,3,4
[+] Author Affiliations
1Neuroimmunology Program, Institut d’Investigació Biomèdica August Pi i Sunyer, University of Barcelona, Barcelona, Spain
2Service of Neurology, Hospital Clinic, Barcelona, Spain
3Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
4Department of Neurology, University of Pennsylvania, Philadelphia
JAMA Neurol. 2016;73(7):891. doi:10.1001/jamaneurol.2016.1164.
Text Size: A A A
Published online


In Reply We thank Gallerini and colleagues for bringing to our attention a new case of opsoclonus associated with a gastric adenocarcinoma. The patient confirms the tight association of older age with a paraneoplastic etiology of the opsoclonus.1

As the authors mention, gastric cancer is rarely seen in patients with paraneoplastic opsoclonus who usually have breast or small-cell lung cancer.2 In addition to the previously reported cases reviewed by Gallerini and colleagues, we would include another case who also presented with Ma2 antibodies.3 Last, patients with opsoclonus and a high suspicion of an underlying tumor should be evaluated according to proposed guidelines to detect the occult neoplasm in paraneoplastic neurological syndromes.4


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





July 1, 2016
Simone Gallerini, MD; Luca Marsili, MD; Roberto Marconi, MD
1Unit of Neurology, Misericordia Hospital, Grosseto, Italy
1Unit of Neurology, Misericordia Hospital, Grosseto, Italy2Department of Neurology and Psychiatry, “Sapienza” University of Rome, Rome, Italy
JAMA Neurol. 2016;73(7):891. doi:10.1001/jamaneurol.2016.1161.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...